TABLE 3.
Cost-effectiveness analysis and incremental cost-effectiveness ratios with regard to pertinent achieving target blood pressure
| C (US$) | E (%) | C/E | ΔC/ΔE | |
| Women (n = 380) | ||||
| NH | 47.2 | 84.2 | 0.6 | ND |
| NM | 62.5 | 88.3 | 0.7 | 3.9 |
| Men (n = 243) | ||||
| NH | 49.5 | 77.5 | 0.6 | ND |
| NM | 62.2 | 79.7 | 0.8 | 5.8 |
| ≤65 years (n = 530) | ||||
| NH | 47.1 | 82.9 | 0.6 | ND |
| NM | 61.7 | 85.8 | 0.7 | 5.0 |
| >65 years (n = 93) | ||||
| NH | 53.9 | 74.4 | 0.7 | ND |
| NM | 66.1 | 78.9 | 0.8 | 2.7 |
| Total (n = 623) | ||||
| NH | 48.0 | 81.8 | 0.6 | ND |
| NM | 62.4 | 84.6 | 0.7 | 5.1 |
C, average cost per patient; E, effectiveness; ND, no data; NH, nitrendipine+hydrochlorothiazide; NM, nitrendipine+metoprolol.